Ross Osborn
Stock Analyst at Cantor Fitzgerald
(1.83)
# 3,153
Out of 4,944 analysts
116
Total ratings
27.1%
Success rate
-6.03%
Average return
Main Sectors:
Stocks Rated by Ross Osborn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ORGO Organogenesis Holdings | Maintains: Overweight | $7 → $9 | $4.92 | +83.11% | 4 | Aug 8, 2025 | |
| LMAT LeMaitre Vascular | Maintains: Neutral | $92 → $95 | $95.15 | -0.16% | 2 | Aug 6, 2025 | |
| CVRX CVRx, Inc. | Reiterates: Overweight | $11 | $7.73 | +42.30% | 3 | Aug 5, 2025 | |
| SIBN SI-BONE | Reiterates: Overweight | $25 | $15.70 | +59.24% | 10 | Aug 5, 2025 | |
| MDXG MiMedx Group | Maintains: Overweight | $11 → $12 | $7.27 | +65.06% | 5 | Jul 31, 2025 | |
| BVS Bioventus | Initiates: Overweight | $12 | $7.56 | +58.84% | 1 | Jul 7, 2025 | |
| XGN Exagen | Maintains: Overweight | $8 → $7 | $9.71 | -27.91% | 6 | May 15, 2025 | |
| LUCD Lucid Diagnostics | Reiterates: Overweight | $2 | $0.98 | +103.85% | 6 | May 15, 2025 | |
| NPCE NeuroPace | Reiterates: Overweight | $17 | $9.32 | +82.40% | 6 | May 14, 2025 | |
| NNOX Nano-X Imaging | Maintains: Overweight | $12 → $9 | $4.55 | +97.80% | 11 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $46 | $31.92 | +44.11% | 6 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $8 | $2.16 | +270.37% | 10 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $24 | $14.76 | +62.60% | 3 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $4 | $1.33 | +200.75% | 4 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $9 | $7.70 | +16.88% | 7 | Jan 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $4.06 | +121.67% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $21 | $5.76 | +264.58% | 10 | Dec 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 | $6.35 | +151.97% | 4 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3.5 | $1.28 | +173.44% | 5 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $2.5 | $0.62 | +303.23% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $1.72 | - | 7 | Apr 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $8.61 | $0.46 | +1,771.74% | 2 | Aug 18, 2023 |
Organogenesis Holdings
Aug 8, 2025
Maintains: Overweight
Price Target: $7 → $9
Current: $4.92
Upside: +83.11%
LeMaitre Vascular
Aug 6, 2025
Maintains: Neutral
Price Target: $92 → $95
Current: $95.15
Upside: -0.16%
CVRx, Inc.
Aug 5, 2025
Reiterates: Overweight
Price Target: $11
Current: $7.73
Upside: +42.30%
SI-BONE
Aug 5, 2025
Reiterates: Overweight
Price Target: $25
Current: $15.70
Upside: +59.24%
MiMedx Group
Jul 31, 2025
Maintains: Overweight
Price Target: $11 → $12
Current: $7.27
Upside: +65.06%
Bioventus
Jul 7, 2025
Initiates: Overweight
Price Target: $12
Current: $7.56
Upside: +58.84%
Exagen
May 15, 2025
Maintains: Overweight
Price Target: $8 → $7
Current: $9.71
Upside: -27.91%
Lucid Diagnostics
May 15, 2025
Reiterates: Overweight
Price Target: $2
Current: $0.98
Upside: +103.85%
NeuroPace
May 14, 2025
Reiterates: Overweight
Price Target: $17
Current: $9.32
Upside: +82.40%
Nano-X Imaging
Apr 1, 2025
Maintains: Overweight
Price Target: $12 → $9
Current: $4.55
Upside: +97.80%
Mar 26, 2025
Reiterates: Overweight
Price Target: $46
Current: $31.92
Upside: +44.11%
Mar 7, 2025
Reiterates: Overweight
Price Target: $8
Current: $2.16
Upside: +270.37%
Mar 5, 2025
Reiterates: Overweight
Price Target: $24
Current: $14.76
Upside: +62.60%
Feb 21, 2025
Reiterates: Overweight
Price Target: $4
Current: $1.33
Upside: +200.75%
Jan 16, 2025
Reiterates: Overweight
Price Target: $9
Current: $7.70
Upside: +16.88%
Jan 7, 2025
Initiates: Overweight
Price Target: $9
Current: $4.06
Upside: +121.67%
Dec 24, 2024
Reiterates: Overweight
Price Target: $21
Current: $5.76
Upside: +264.58%
Nov 5, 2024
Reiterates: Overweight
Price Target: $16
Current: $6.35
Upside: +151.97%
Aug 8, 2024
Reiterates: Overweight
Price Target: $3.5
Current: $1.28
Upside: +173.44%
May 16, 2024
Reiterates: Overweight
Price Target: $2.5
Current: $0.62
Upside: +303.23%
Apr 12, 2024
Reiterates: Neutral
Price Target: n/a
Current: $1.72
Upside: -
Aug 18, 2023
Reiterates: Neutral
Price Target: $8.61
Current: $0.46
Upside: +1,771.74%